Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, Yesterday
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.

Serum CRP, ECOG scores, treatment intensity predict survival in metastatic SCCHN

10 Jul 2017
Time from diagnosis to relapse, treatment intensity, C-reactive protein (CRP) and leukocyte levels, and Eastern Cooperative Oncology Group (ECOG) scores are independent predictors of prognosis in metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN), shows a new study.

Multivariable analysis of 128 cetuximab-treated SCCHN patients showed that a less intensive therapy was independently associated with worse overall survival (OS; hazard ratio [HR], 2.560; 95 percent CI, 1.510 to 4.341; p<0.001) than those who received polychemotherapy with cetuximab.

Similarly, high ECOG scores (HR, 2.048; 1.319 to 3.179; p=0.001), high CRP (HR, 1.651; 1.058 to 2.575; p=0.027) and leukocyte (HR, 2.224; 1.416 to 3.495; p=0.001) levels and shorter time from primary diagnosis to palliative therapy (HR, 1.830; 1.185 to 2.824; p=0.006) were independent predictors of poor prognosis.

A prognostic score for the patients was generated by assigning each of the five factors one point. Patients that had zero points had a median OS of 21.5 months.

In contrast, those with one, two, three, four and five points had median OS of 12.7, 6.8, 4.9, 0.7 and 0.6 months, respectively (p<0.001).

The median OS of patients with zero to one risk factor (13.6 months) was significantly greater than those with two to three risk factors (6.1 months; p<0.001) which, in turn, was significantly greater than those with four to five risk factors (0.7 months; p<0.001).

All participants recruited were diagnosed with metastatic or recurrent SCCHN and received either cetuximab alone or in combination with chemotherapy. Prognostic scores for OS were derived using measurements from serum samples and patient clinical characteristics.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, Yesterday
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.